Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

BACKGROUND AND AIMS An evaluation is made of the utility of fecal calprotectin in predicting relapse in patients with inflammatory bowel disease (IBD). The possible differences in its predictive capacity in Crohn's disease (CD) versus ulcerative colitis (UC), and the different phenotypes, are also examined. METHODS This is a prospective study with 135 patients diagnosed with IBD in clinical remission for at least 3 months. The patients submitted a stool sample within 24 hours after the baseline visit, for the measurement of fecal calprotectin. All patients were followed-up on for one year. RESULTS Sixty-six patients had CD and 69 UC. Thirty-nine (30%) suffered from relapse. The fecal calprotectin concentration was higher among the patients with relapse than in those that remained in remission: 444 µg/g (95% CI 34-983) versus 112 µg/g (95% CI 22-996); p<0.01. Patients with CD and calprotectin>200 µg/g relapsed 4 times more often than those with lower marker concentrations. In UC, calprotectin>120 µg/g was associated with a 6-fold increase in the probability of disease activity outbreak. The predictive value was similar in UC and CD with colon involvement and inflammatory pattern. In this group, calprotectin>120 µg/g predicted relapse risk with a sensitivity of 80% and a specificity of 60%. Relapse predictive capacity was lower in patients with ileal disease. CONCLUSIONS Fecal calprotectin may be a useful marker for predicting relapse in patients with IBD. Its predictive value is greater in UC and CD with colon involvement and inflammatory pattern, compared with ileal CD.

[1]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[2]  G. Corrao,et al.  Intestinal permeability test as a predictor of clinical course in Crohn's disease , 1999, American Journal of Gastroenterology.

[3]  M. Castro,et al.  Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases , 2008, Inflammatory bowel diseases.

[4]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[5]  P. Rutgeerts,et al.  Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.

[6]  S. Kugathasan,et al.  Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[7]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[8]  R. D'Incà,et al.  Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.

[9]  M. Färkkilä,et al.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.

[10]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[11]  A. Røseth,et al.  Inflammatory biomarkers predict relapse in IBD , 2005, Gut.

[12]  Y. Yazdanpanah,et al.  Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series , 2011, Alimentary pharmacology & therapeutics.

[13]  J. Belaiche,et al.  Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission , 2000, International Journal of Colorectal Disease.

[14]  J. Martín-de-Carpi,et al.  Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies. , 2010, Journal of Crohn's & colitis.

[15]  A. Cohen,et al.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.

[16]  R. Modigliani,et al.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.

[17]  J. Wright,et al.  Predictors of acute relapse of Crohn's disease , 1987, Digestive Diseases and Sciences.

[18]  M. Serghini,et al.  Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[19]  J. Panés,et al.  Review article: stem cell therapies for inflammatory bowel disease – efficacy and safety , 2010, Alimentary pharmacology & therapeutics.

[20]  J. Mate,et al.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.

[21]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[22]  R. Modigliani.  Endoscopic management of inflammatory bowel disease. , 1994, The American journal of gastroenterology.

[23]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[24]  M. S. Fernández-García,et al.  Kaposi's sarcoma: an opportunistic infection by human herpesvirus-8 in ulcerative colitis. , 2010, Journal of Crohn's & colitis.

[25]  J. Panés,et al.  New MRI modalities for assessment of inflammatory bowel disease , 2010, Gut.

[26]  S. Saverymuttu.  Clinical remission in Crohn's disease--assessment using faecal 111In granulocyte excretion. , 1986, Digestion.

[27]  Paul Rutgeerts,et al.  C-Reactive Protein as a Marker for Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[28]  Takayuki Yamamoto,et al.  Systemic and Local Cytokine Production in Quiescent Ulcerative Colitis and Its Relationship to Future Relapse: A Prospective Pilot Study , 2005, Inflammatory bowel diseases.

[29]  P. Hernández-Sampelayo,et al.  Contribution of nurses to the quality of care in management of inflammatory bowel disease: a synthesis of the evidence. , 2010, Journal of Crohn's & colitis.

[30]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[31]  J. Gisbert,et al.  Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal , 2007 .

[32]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[33]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[34]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[35]  P. Rutgeerts,et al.  The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[36]  M. Campieri,et al.  A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. , 1986, Gastroenterology.